Myomo Reports Record Third Quarter Financial Results
Myomo, Inc. (NYSE American: MYO) is a pioneering company specializing in wearable medical robotics. The brand is dedicated to enhancing functionality for individuals experiencing neurological challenges and upper-limb paralysis. Recently, Myomo announced a remarkable achievement in its financial performance for the latest quarter.
Third Quarter Highlights
The financial and operational highlights for Myomo during this period revealed significant advancements in multiple metrics compared to the same quarter the previous year. Notably, the total revenue soared to a staggering $9.2 million, representing an impressive increase of 81%. Meanwhile, product revenue shot up an astonishing 83%, indicating robust demand for MyoPro units, which serve to aid users with mobility issues.
Record-Breaking Achievements
- Sales of MyoPro units hit 161, showcasing a growth of 35% in revenue units.
- The total number of authorizations and orders surged, with a record 225 MyoPro units ordered, representing a notable 44% increase.
- The backlog of orders as of September 30, 2024, indicated a promising future, standing at 316 units, which is an increase of 71%.
- A significant addition of 645 new candidates to the patient pipeline underlines the growing awareness and adoption of Myomo's technologies, marking a 69% rise.
Management Insights
Paul R. Gudonis, chairman and chief executive officer of Myomo, emphasized the company’s rigorous outreach and increasing educational efforts targeting Medicare beneficiaries and maintaining high-quality operational standards. He expressed satisfaction with the consecutive quarters of record-setting financial performance, which illustrates the efficacy of their growth strategies.
Financial Composition and Performance
In terms of gross revenue, Myomo reported gross margin at 75.4%, a substantial rise from 68.7% compared to the previous year, indicative of improved product margins due to enhanced average selling prices (ASP). The ASP for MyoPro units has risen to approximately $57,200, reflecting a growth of 35% year-on-year.
Operational Developments
Operating expenses also saw an increase, totaling $7.9 million for the quarter, which is an elevation of 43% year-over-year. The investments in staffing and support for engineering capabilities have drove this increase. Despite the rise in operating expenses, Myomo’s operational loss has reduced, highlighting improved cost management strategies.
Patient Pipeline Growth
As of the end of the quarter, the total patient pipeline stood at 1,263, showcasing an increase of 21% from the previous year. The onboarding of new patients, coupled with a growing backlog, sets a solid foundation for sustained growth going forward.
Looking Ahead: Business Strategies
With an optimistic outlook, Myomo anticipates a continuation of revenue growth into the fourth quarter. Projections indicate potential revenues between $9.5 million and $10.5 million, leading to an overall annual revenue estimate between $30 million and $31 million. This growth forecast is a testament to emerging market demands and the efficacy of operational strategies in place.
Conference Call Planned
Myomo will be hosting a conference call shortly to discuss the impressive results and expectations. Interested parties are encouraged to participate as Myomo continues to take substantial steps towards enhancing its market position.
Frequently Asked Questions
What are the key financial figures for Myomo this quarter?
Myomo reported record total revenue of $9.2 million, marking an 81% increase, with product revenue increasing by 83% compared to the previous year.
What advancements has Myomo made in its patient pipeline?
Myomo added 645 patients to its pipeline this quarter, reflecting a 69% increase year-over-year, demonstrating strong demand for its products.
How has Myomo managed operational expenses this quarter?
Operating expenses climbed to $7.9 million, a 43% increase, primarily due to higher payroll expenses for expanded staff focused on engineering and clinical support.
When is Myomo's conference call scheduled?
The conference call is set for later today, where management will discuss the quarter's results and future expectations.
What are the future revenue projections for Myomo?
Myomo expects fourth-quarter revenues to range between $9.5 million to $10.5 million, leading to an annual total of approximately $30 million to $31 million.
